KLRS - NASDAQ
Kalaris Therapeutics Inc
$4.70
-0.42%Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
At a Glance
Live Snapshotklrs
Operating Expenses
Last Annual Value
46.14M
3-Year CAGR
49%
5-Year CAGR
-8%
10-Year CAGR
-4%
Kalaris Therapeutics Inc Competitors Analysis of Operating Expenses
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Kalaris Therapeutics Inc NASDAQ:KLRS | 46.14M | 50.8% | -22.8% | N/A | |
 Ovid Therapeutics Inc. NASDAQ:OVID | 49.39M | -6.1% | -10.1% | 8.2% | |
 Artiva Biotherapeutics, Inc. NASDAQ:ARTV | 88.01M | 11.1% | 9.8% | N/A | |
 Shattuck Labs, Inc. NASDAQ:STTK | 48.84M | -18.3% | -7.9% | N/A | |
 Context Therapeutics Inc. NASDAQ:CNTX | 39.70M | 16.6% | 30.4% | N/A | |
 Metagenomi, Inc. Common Stock NASDAQ:MGX | 115.91M | 59.0% | 37.2% | N/A | |
 Adverum Biotechnologies, Inc. NASDAQ:ADVM | 140.16M | 1.9% | -1.8% | 9.6% | |
 ALX Oncology Holdings Inc. NASDAQ:ALXO | 100.85M | -16.0% | 3.8% | N/A | |
 Fractyl Health, Inc. Common Stock NASDAQ:GUTS | 95.69M | 23.4% | 21.0% | N/A | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 36.51M | -16.2% | -2.8% | N/A | |
 Oramed Pharmaceuticals Inc. NASDAQ:ORMP | 15.10M | -4.1% | -10.9% | 4.0% |
Kalaris Therapeutics Inc Fair Value Envelope
Related Guides
Continue your KLRS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.